Plasma concentrations of propranolol in patients with essential hypertension A. LehtonenJ. KantoT. Kleimola Originals Pages: 155 - 157
Dose-titrated, double-blind, cross-over comparison of a selective beta-blocker and methyldopa in the treatment of hypertension P. A. RoutledgeL. V. ZrinzoM. D. Rawlins Originals Pages: 159 - 162
Controlled clinical investigation of trimeprazine as a sleep-inducer in normal subjects K. KayedT. HansenO. B. Godtlibsen Originals Pages: 163 - 167
Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment U. AbshagenH. RennekampG. Luszpinski Originals Pages: 169 - 176
Elimination of canrenone in congestive heart failure and chronic liver disease L. JacksonR. BranchL. Ramsay Originals Pages: 177 - 179
Methodology and results of a survey of adverse reactions to a drug in private practice A. SprietC. SprietP. Simon Originals Pages: 181 - 192
Agranulocytosis during treatment with clozapine J. Idänpään-HeikkiläE. AlhavaI. P. Palva Originals Pages: 193 - 198
Clozapine-induced agranulocytosis: A situation report up to August 1976 B. AndermanR. W. Griffith Originals Pages: 199 - 201
Bioavailability of two hydrochlorothiazide preparations B. BeermannM. Groschinsky-GrindB. Lindström Originals Pages: 203 - 205
Plasma concentrations, bioavailability and dissolution of chlorpropamide T. TaylorD. F. AssinderJ. S. Burton Originals Pages: 207 - 212
Serum glycoside concentrations after single or repeated intravenous doses ofβ-methyl-digoxin and digoxin J. MarinowA. OlcayW. Weiss Originals Pages: 213 - 218
First pass hydroxylation of nortriptyline: Concentrations of parent drug and major metabolites in plasma G. AlvánO. BorgåB. Siwers Originals Pages: 219 - 224
Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency M. Pérez-MateoS. Erill Originals Pages: 225 - 231
Towards a more rational regulation of the development of new meidcines Special Article Pages: 233 - 238